Alexion Pharmaceuticals, Inc. logo
Alexion Pharmaceuticals, Inc. ALXN

Alexion Pharmaceuticals, Inc. EBITDA 2011-2026 | ALXN

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Alexion Pharmaceuticals, Inc.

2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
3.11 B 2.45 B 1.91 B 1.12 B 1.12 B 799 M 963 M 567 M 454 M 245 M

All numbers in USD currency

Indicator range from annual reports

Maximum Minimum Average
3.11 B 245 M 1.27 B

References

  1. Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Biotechnology industry

Issuer EBITDA Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-508 M - 2.43 % $ 254 M germanyGermany
Acer Therapeutics Acer Therapeutics
ACER
-24.5 M - 2.71 % $ 14 M usaUSA
Agenus Agenus
AGEN
-146 M $ 3.27 -1.8 % $ 1.17 M usaUSA
Agios Pharmaceuticals Agios Pharmaceuticals
AGIO
-467 M $ 29.33 -2.98 % $ 1.7 B usaUSA
I-Mab I-Mab
IMAB
13.8 M - - $ 866 M chinaChina
Akebia Therapeutics Akebia Therapeutics
AKBA
24.8 M $ 1.26 -3.44 % $ 324 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
-21.6 M $ 0.24 1.1 % $ 5.73 B britainBritain
Aldeyra Therapeutics Aldeyra Therapeutics
ALDX
-35 M $ 5.49 0.52 % $ 330 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-9.76 M - -10.17 % $ 12.2 K usaUSA
Alector Alector
ALEC
-150 M $ 2.26 -7.2 % $ 233 M usaUSA
Biophytis SA Biophytis SA
BPTS
-26.8 M - -13.47 % $ 169 M franceFrance
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-242 M - - $ 1.01 B usaUSA
Aligos Therapeutics Aligos Therapeutics
ALGS
-86.6 M $ 7.02 -0.21 % $ 451 M usaUSA
Alkermes plc Alkermes plc
ALKS
281 M $ 29.32 -2.61 % $ 4.83 B irlandaIrlanda
Allogene Therapeutics Allogene Therapeutics
ALLO
-314 M $ 2.57 -7.73 % $ 403 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
-16.2 M - - $ 26.5 M usaUSA
Alnylam Pharmaceuticals Alnylam Pharmaceuticals
ALNY
557 M $ 330.95 -0.59 % $ 43.4 B usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
-8.18 M - -1.52 % $ 24.7 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-7 M - -18.52 % $ 27.3 M britainBritain
Altimmune Altimmune
ALT
-103 M $ 4.2 -2.55 % $ 298 M usaUSA
ALX Oncology Holdings ALX Oncology Holdings
ALXO
-142 M $ 2.11 0.09 % $ 110 M usaUSA
Amgen Amgen
AMGN
14.2 B $ 387.85 0.03 % $ 209 B usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
172 M $ 20.22 -0.05 % $ 945 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
-67.4 M $ 13.62 -1.3 % $ 5.55 B irlandaIrlanda
AIM ImmunoTech AIM ImmunoTech
AIM
-19.9 M $ 0.92 5.25 % $ 44.2 M usaUSA
AnaptysBio AnaptysBio
ANAB
-114 M $ 54.61 -0.8 % $ 1.55 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
-81.2 M $ 14.44 0.53 % $ 212 M usaUSA
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
68.3 M $ 75.31 1.91 % $ 1.45 B usaUSA
Annexon Annexon
ANNX
-152 M $ 5.38 -3.93 % $ 739 M usaUSA
Annovis Bio Annovis Bio
ANVS
-45 M $ 2.6 -2.99 % $ 23.5 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
-88.1 M - 1052.0 % $ 415 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-233 M - -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
-16.7 M - 4.01 % $ 150 M canadaCanada
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-136 M - - $ 86.2 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
220 M - - - russiaRussia
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
57 M $ 20.53 -2.05 % $ 2.59 B usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
1.19 M $ 0.78 -0.67 % $ 4.25 M chinaChina
AIkido Pharma AIkido Pharma
AIKI
-11.4 M - 1.93 % $ 17.4 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
-285 M - - $ 3.67 B usaUSA
Akouos Akouos
AKUS
-84.3 M - 0.23 % $ 488 M usaUSA
Aprea Therapeutics Aprea Therapeutics
APRE
-15.5 M $ 0.88 -3.71 % $ 3.18 M usaUSA
Aptevo Therapeutics Aptevo Therapeutics
APVO
-24.2 M $ 7.28 -0.55 % $ 2.01 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
-123 M - -0.23 % $ 916 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
-47.3 M - 3.16 % $ 1.9 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
-30.1 M $ 3.99 -0.15 % $ 346 M usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
-92.1 M $ 8.11 -1.44 % $ 219 M israelIsrael
Ardelyx Ardelyx
ARDX
-37.9 M $ 6.32 -3.54 % $ 1.52 B usaUSA
Aileron Therapeutics Aileron Therapeutics
ALRN
-65 M - 10.36 % $ 9.8 M usaUSA
argenx SE argenx SE
ARGX
-349 M $ 762.51 -0.58 % $ 25 B niderlandNiderland